See more : SG Company S.p.A. (SGC.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Gubra A/S (GUBRA.CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gubra A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Chongqing Port Co.,Ltd. (600279.SS) Income Statement Analysis – Financial Results
- CSC Financial Co., Ltd. (6066.HK) Income Statement Analysis – Financial Results
- Dacotah Banks, Inc. (DBIN) Income Statement Analysis – Financial Results
- The Toho Bank, Ltd. (8346.T) Income Statement Analysis – Financial Results
- Sunrise Energy Metals Limited (SREMF) Income Statement Analysis – Financial Results
Gubra A/S (GUBRA.CO)
About Gubra A/S
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 205.01M | 199.38M | 255.33M | 172.30M |
| Cost of Revenue | 90.07M | 101.64M | 89.45M | 79.95M |
| Gross Profit | 114.94M | 97.75M | 165.88M | 92.35M |
| Gross Profit Ratio | 56.06% | 49.02% | 64.97% | 53.60% |
| Research & Development | 89.23M | 56.84M | 27.06M | 34.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.50M | 58.26M | 43.04M | 39.14M |
| Other Expenses | 8.63M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 164.35M | 99.03M | 77.21M | 76.49M |
| Cost & Expenses | 254.42M | 200.67M | 166.65M | 156.44M |
| Interest Income | 4.69M | 204.00K | 6.00K | 2.00K |
| Interest Expense | 4.89M | 1.52M | 1.69M | 1.37M |
| Depreciation & Amortization | 9.95M | 3.12M | 6.56M | 6.24M |
| EBITDA | -28.06M | 11.16M | 95.40M | 21.41M |
| EBITDA Ratio | -13.69% | 7.35% | 38.74% | 14.18% |
| Operating Income | -49.42M | 7.78M | 88.79M | 15.05M |
| Operating Income Ratio | -24.11% | 3.90% | 34.77% | 8.73% |
| Total Other Income/Expenses | 6.51M | 7.55M | -1.57M | -2.18M |
| Income Before Tax | -42.90M | 6.26M | 87.10M | 13.68M |
| Income Before Tax Ratio | -20.93% | 3.14% | 34.11% | 7.94% |
| Income Tax Expense | 1.62M | 1.95M | 19.16M | 989.00K |
| Net Income | -44.52M | 4.31M | 67.94M | 12.69M |
| Net Income Ratio | -21.72% | 2.16% | 26.61% | 7.37% |
| EPS | -2.93 | 0.26 | 4.16 | 0.78 |
| EPS Diluted | -2.93 | 0.26 | 4.16 | 0.78 |
| Weighted Avg Shares Out | 15.17M | 16.32M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 15.17M | 16.32M | 16.32M | 16.32M |
Source: https://incomestatements.info
Category: Stock Reports